Bristol Myers Squibb

Headlines · 2

1. 4d
   Anthropic expands Claude drug discovery with six partnerships

   Anthropic announced research partnerships with six drug-development organizations, began its own drug-discovery work and acquired Mithril Medicine, whose founder used Claude to coordinate 11 external laboratories and two rare-disease programs. In disclosed partner work, Claude helped design molecules, analyze laboratory data and review manufacturing records, including an experiment at BigHat Biosciences that tested about 1,010 variants in roughly 10 weeks. Anthropic said most of the research remains early and preclinical, with little or no human testing yet.

   Hacker News 首页（100+ 分） · 🔥 0
2. Oct 23
   Pathos AI Raises $237M Series E at $3B Valuation

   Pathos AI announced a $237 million Series E financing at a $3 billion post-money valuation, led by Bristol Myers Squibb with participation from several unnamed returning backers. The company develops cancer drugs with its agentic AI platform, Foundry, which it says can access about 200 petabytes of oncology data. Pathos also announced agreements with Bristol Myers Squibb and Tempus AI involving Foundry access and de-identified data on Alzheimer's disease and other neurological conditions. The supplied reports do not independently validate the platform's performance claims or provide independent clinical-outcome data for Foundry-assisted development.

   SiliconANGLE AI · 🔥 0

Experience and discussion from the community

Share my Bristol Myers Squibb experienceAsk about Bristol Myers Squibb